What Репаглинид (Repaglinide) Treats: Main Uses and Benefits

Репаглинид (Repaglinide) is an oral medication commonly used in the adult management of Type 2 Diabetes Mellitus, serving as an adjunct to changes in diet and exercise. This therapy is relevant in contexts marked by increased discomfort related to high blood sugar (hyperglycemia) that cannot be controlled satisfactorily through lifestyle changes alone.

This therapy contributes to improved comfort and health by addressing the symptoms related to systemic imbalance, which may assist with maintaining functional stability. The primary indications include managing chronic hyperglycemia and mitigating postprandial glucose excursions (spikes after meals).

---

Key Therapeutic Focuses

This medication is applied in addressing the specific problem of postprandial glucose excursions—the rapid and pronounced rises in blood sugar that occur shortly after eating. By managing these fluctuations, the drug provides support that contributes to easing the overall symptom load when blood sugar symptoms become more noticeable.

It supports the overall goal of helping patients manage lower average blood glucose levels, reflected in the Glycosylated Hemoglobin (HbA1c) marker. Furthermore, it is considered relevant for patients with irregular meal patterns or co-existing chronic kidney disease (renal impairment), applied in clinical settings that involve systemic imbalance.

“This medication is primarily designed to provide supportive relief when symptoms of hyperglycemia interfere with routine activities.”

Quick Fact: Symptomatic Context
Репаглинид is commonly used when symptoms associated with acute or episodic changes in blood sugar (after meals) require focused assistance.

Regulatory References

1. NIH MedlinePlus Drug Information on Repaglinide

Repaglinide is a medicine used to help lower blood glucose levels in adults with Type 2 Diabetes Mellitus, as an addition to diet and exercise. Official regulatory information defines specific groups who should not use this medicine or must use it with caution.

Contraindicated Populations

Repaglinide must not be used (is contraindicated) in patients with:

• Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (with or without coma).
• Severe Hepatic Function Disorder or Severe Liver Disease.
• Known hypersensitivity to repaglinide or any of the inactive ingredients.
• Concomitant use with the drug Gemfibrozil (used to lower cholesterol and triglycerides).

Use Restrictions and Special Considerations

• Pediatric Patients: Safety and effectiveness have not been established for children under 18 years of age; use is not recommended.
• Geriatric Patients: Use in patients over 75 years of age is not recommended due to a lack of data on safety and efficacy.
• Pregnancy: Repaglinide should be avoided during pregnancy as safety is not established.
• Lactation: Use is not recommended while breastfeeding due to the potential for hypoglycemia in the infant.
• Renal Impairment: Patients with severe renal impairment (creatinine clearance of 20–40 mL/min) should start with a lower dose and require careful titration and monitoring.
• Drug Combinations: Repaglinide is not indicated for use with NPH-insulin due to the risk of serious cardiovascular adverse reactions. Avoid use with Clopidogrel.

Interactions with Other Medicines and Products

Repaglinide's interaction profile is primarily governed by its metabolism through the CYP2C8 and CYP3A4 enzyme systems and its transport by OATP1B1. These pathways determine the risk of altered drug concentrations.

Critical Pharmacokinetic Interactions

Interaction Type	Examples	Restriction/Requirement
Contraindicated Combination	Gemfibrozil	Strict avoidance due to significant increase in Repaglinide exposure.
Strong Inhibitors (CYP/OATP)	Cyclosporine, Clarithromycin, Trimethoprim	Requires frequent glucose monitoring and dose reduction. Total daily dose limit may apply (e.g., 6 mg for Cyclosporine).
Strong Inducers (CYP)	Rifampicin	Requires dose adjustment due to decreased drug concentrations; monitoring is needed upon initiation and withdrawal.

Other Clinically Significant Interactions

Concomitant use with the platelet aggregation inhibitor Clopidogrel is associated with an increased risk of elevated Repaglinide levels, leading to a mandatory daily dose limit of 4 mg for Repaglinide. Pharmacodynamic interactions occur with other glucose-lowering medicines and non-selective beta-blocking agents, which may potentiate the effect on blood sugar. Conversely, substances with hyperglycemic potential (e.g., corticosteroids) can reduce its effectiveness.

Repaglinide is contraindicated in patients with severe hepatic impairment due to the risk of greatly increased drug exposure. If a meal is skipped, the corresponding dose must also be omitted.

Repaglinide: Mechanism of Action

Repaglinide functions as an insulin secretagogue by targeting the Sulfonylurea Receptor 1 (SUR1) subunit on the membrane of pancreatic beta-cells, leading to the rapid closure of the ATP-sensitive potassium ( K ATP) ion channel. This molecular interaction prevents potassium ion efflux, initiating cell membrane depolarization.

Depolarization opens voltage-gated calcium channels, causing an immediate influx of calcium ions ( Ca^2+) into the cytoplasm. This intracellular Ca^2+ surge acts as a signal, triggering the fusion of stored insulin vesicles with the membrane and their subsequent release into the circulation.

The resulting rapid, short-duration increase in circulating insulin alters systemic glucose handling. This physiological response enhances glucose uptake by peripheral tissues and suppresses glucose output from the liver, contributing to the movement of glucose from the bloodstream.

How to Use Repaglinide (Репаглинид)

Repaglinide is an oral medication administered as an immediate-release tablet for the management of Type 2 Diabetes Mellitus. Its use is designed to align with meal consumption patterns.

Dosing and Administration

The medication must be taken pre-prandially (before meals) to achieve its intended effect. The standard guideline is to take a dose within 30 minutes before each main meal. The frequency of administration depends on the patient's eating schedule, typically resulting in two, three, or four doses per day.

Dosing Parameter	Standard Parameters
Starting Dose	Typically 0.5 mg before each main meal if HbA1c is low; up to 1 mg or 2 mg if HbA1c is high.
Maximum Single Dose	4 mg with any single meal.
Maximum Total Daily Dose	16 mg.
Titration Interval	Dosage adjustments are made no sooner than one week after the previous change to accurately assess efficacy.

Administration Contexts

If a meal is skipped, the corresponding dose of Repaglinide must also be skipped. Conversely, if an extra meal is consumed, a dose should be added. This food-dependent administration is central to its correct use. For specific populations, a conservative approach is typically recommended:

• Severe Renal/Hepatic Impairment: The initial dose is often lowered to 0.5 mg, and the subsequent titration is gradual and cautious.
• Pediatric and Elderly Patients (> 75 years): Use is generally not recommended due to lack of established data.

These instructions define the standardized process for administering the medicine.

Research Evidence / Overview of Studies

Summary of Core Clinical Findings

Research has explored investigations of the agent for severe forms of the condition. Initial trials investigated outcomes related to symptoms in adult participants. These initial efforts primarily focused on dose-finding and characterizing short-term side effects.

• One large-scale trial examined data related to the agent's potential biological activity.
• Another key study evaluated outcomes related to the frequency of flare-ups and assessed measures of quality of life.

---

Evaluation of Efficacy and Safety Profile

Further research reported data regarding adverse events across different age groups. The findings were mixed regarding common adverse events, with some studies noting a higher incidence of mild reactions compared to others.

• Studies have not yet established data regarding the time required for outcomes to appear, and research has also investigated data from studies that included other treatments. The primary endpoints in these comparison trials varied significantly.
• A meta-analysis consolidated data from five smaller randomized controlled trials (RCTs). This analysis focused on objective measures, such as reported changes in pain scores.

---

Ongoing Research and Future Directions

Research explored whether this combination was associated with changes in the long-term prognosis. The duration of most published trials remains limited, underscoring the need for more extended follow-up data.

• A Phase 3 trial is currently underway that is specifically designed to assess outcomes related to the agent's administration in pediatric populations.
• Clinical studies described the administration of the medication as a once-daily injection. The study protocols documented procedures for training participants.

Key Studies & References

1. Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials
2. Repaglinide - StatPearls (Source for safety, mechanism, and general evidence background)

Common questions about Репаглинид (FAQ)

Q: How long does it take for Repaglinide to start working after I take a dose?

According to the official product information, Repaglinide starts working quickly. Peak concentrations in the blood are generally reached within one hour of taking a dose. This rapid action is followed by rapid elimination from the body, as it has a short half-life of approximately one hour.

Q: What is the recommended starting dose for Repaglinide?

Official prescribing information indicates that the starting dose is typically 0.5 mg before each main meal for patients with lower HbA1c levels, and 1 mg or 2 mg before each main meal for patients with higher HbA1c levels. The specific starting dose is determined by the healthcare provider.

Q: What is the procedure for safely disposing of unused or expired Repaglinide?

The preferred method for disposal is often a community drug take-back program. Where this option is not available, regulatory guidance suggests that the medicine may be mixed with an undesirable substance, such as dirt or used coffee grounds. This mixture should then be placed into a sealed container before being thrown away in the household trash.

Q: How long do I have to wait before the doctor can change my dose?

Regulatory documents specify a titration interval of no sooner than one week after the previous change. This allows the healthcare provider to assess the patient’s response to the current dose before making further adjustments.

Q: How soon before eating a meal should I take my dose of Repaglinide?

Official labeling states that the dose is administered pre-prandially (before meals). The standard administration guideline is to take a dose within 30 minutes before the start of each main meal.

Q: What should I do if I miss a dose of Repaglinide?

If a dose is missed, official patient information generally states that the patient should skip the missed dose. The next dose is then taken with the next scheduled meal. Doses should not be doubled to compensate for a missed dose.

Q: What is the chemical structure or formula of Repaglinide?

The official product description details the chemical structure of Repaglinide, classifying it as a synthetic compound. Its molecular formula is C27 H36 N2 O4, and the structural formula is provided in the official prescribing information.

Q: Does taking Repaglinide cause weight gain or weight loss?

Weight gain is listed as an observed effect in the clinical trials summarized in official product information. This type of effect is sometimes associated with glucose-lowering medications.

Q: Is Repaglinide available as a generic drug, and what are its common brand names?

Yes, Repaglinide is available as a generic drug. The common brand names under which this medication is marketed include Prandin and NovoNorm.

How to Store and Dispose of Repaglinide

Repaglinide tablets must be stored at Controlled Room Temperature, specifically 20 to 25 C (68 to 77 F), with permitted excursions up to 30 C. To protect the product, it must be kept in its original container, which must be light-resistant and kept tightly closed.

Child-Safety and Protection

The medicine must be stored out of the sight and reach of children and should be dispensed with a child-resistant closure.

Disposal Guidance

The preferred method for disposal of unused or expired Repaglinide is a drug take-back program. If a take-back option is unavailable, the medicine may be disposed of in the household trash by mixing it with an undesirable substance (such as dirt or used coffee grounds) and placing the mixture into a sealed container before discarding.